INVESTIGATIONS OF AN OPTIMAL INHALER TECHNIQUE WITH THE USE OF URINARY SALBUTAMOL EXCRETION AS A MEASURE OF RELATIVE BIOAVAILABILITY TO THE LUNG

被引:76
作者
HINDLE, M
NEWTON, DAG
CHRYSTYN, H
机构
[1] UNIV BRADFORD,SCH PHARM,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND
[2] ST LUKES HOSP,CHEST CLIN,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND
关键词
D O I
10.1136/thx.48.6.607
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background-A simple non-invasive method, in which a urine sample is taken 30 minutes after drug administration, has previously been shown to be a measure of the relative bioavailability of salbutamol to the lungs. This technique has been used to determine an optimal inhaler technique with commercially available metered dose inhalers (MDI). Methods-Ten healthy subjects were trained in the use of MDIs. Each inhaled 4 x 100 mug salbutamol in a series of experiments to examine the relative bioavailability to the lung after different respiratory manoeuvres. Urine collection intervals were 0-0.5 hours and 0.5-24 hours after administration. Results-There was significantly greater elimination of unchanged salbutamol 30 minutes after administration, indicating a greater relative bioavailability of salbutamol to the lungs after (1) exhaling gently to residual volume rather than to functional residual capacity before inhalation; (2) slow inhalation (10 l/min) compared with fast inhalation (50 l/min); (3) breath holding for 10 seconds after inhalation compared with no breath holding. Conclusions-All patient information leaflets and healthcare personnel should standardise the instructions given to patients and should adopt the inhalation method proposed.
引用
收藏
页码:607 / 610
页数:4
相关论文
共 12 条
[1]   A METHOD FOR DETERMINATION OF THE ABSOLUTE PULMONARY BIOAVAILABILITY OF INHALED DRUGS - TERBUTALINE [J].
BORGSTROM, L ;
NILSSON, M .
PHARMACEUTICAL RESEARCH, 1990, 7 (10) :1068-1070
[2]  
DAVIES DS, 1984, EUR J RESPIR DIS, V65, P141
[3]   DETERMINATION OF THE RELATIVE BIOAVAILABILITY OF SALBUTAMOL TO THE LUNG FOLLOWING INHALATION [J].
HINDLE, M ;
CHRYSTYN, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (04) :311-315
[4]  
LIPWORTH BJ, 1989, EUR J CLIN PHARMACOL, V37, P567
[5]  
NEWMAN SP, 1982, EUR J RESPIR DIS, V63, P57
[6]  
NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52
[7]  
NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3
[8]   PATIENT ERROR IN USE OF BRONCHODILATOR METERED AEROSOLS [J].
OREHEK, J ;
GAYRARD, P ;
GRIMAUD, C ;
CHARPIN, J .
BRITISH MEDICAL JOURNAL, 1976, 1 (6001) :76-76
[9]   EFFECT OF DEPTH OF INHALATION ON AEROSOL PERSISTENCE DURING BREATH HOLDING [J].
PALMES, ED ;
WANG, CS ;
GOLDRING, RM ;
ALTSHULER, B .
JOURNAL OF APPLIED PHYSIOLOGY, 1973, 34 (03) :356-360
[10]   USE OF PRESSURIZED AEROSOLS BY ASTHMATIC-PATIENTS [J].
PATERSON, IC ;
CROMPTON, GK .
BRITISH MEDICAL JOURNAL, 1976, 1 (6001) :76-77